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intervention measures for LDL, HDL, triglycerides, total choles-
terol, adherence and quality-of-life. A random-effects meta-
analysis combined data between pharmacist-intervention and
standard-care groups. Chi-square tested heterogeneity of effects.
Publication bias was assessed using funnel plots and Begg-
Mazumdar statistic. RESULTS: Fifty-one studies were found; 22
met inclusion/exclusion criteria. Study settings included medical
clinic/center (n = 11), community pharmacy (n = 8), hospital
(n = 2) and patient homes (n = 1). Patient education (77%) and
medication management (73%) were most common interven-
tions. The average patient follow-up period was 9.8  6.4
months. Quality of pharmacist-intervention studies was consid-
ered “fair” (65%, SD = 6.6%). Total cholesterol was signiﬁ-
cantly reduced from baseline (34.3  10.3 mg/dL, p < 0.001)
and also signiﬁcantly above control groups (22.0  10.4 mg/dL,
p = 0.034). LDL was reduced signiﬁcantly from baseline
(38.6  12.4 mg/dL, p = 0.002); but not signiﬁcantly more than
controls (22.1  12.0 mg/dL, p = 0.065). A clinically relevant
but not statistically signiﬁcant reduction in triglycerides was
found. Patients’ adherence to pharmacotherapeutic regimens (3/9
studies reported signiﬁcant results after pharmacists’ interven-
tions) and quality of life (2/2 signiﬁcant) were considered
possibly not sensitive and possibly sensitive to pharmacist
interventions, respectively. CONCLUSION: Total cholesterol
is sensitive to pharmacist’s interventions while LDL and
triglycerides levels are possibly sensitive to those interventions.
Further research should evaluate speciﬁc determinants of
pharmacist-sensitive outcomes.
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OBJECTIVE: New members of the TNF-signaling superfamily,
osteoprotegerin (OPG) and receptor activator of nuclear
factor-kB ligand (RANKL), are thought to play an important role
in vascular calciﬁcation and bone remodeling and might repre-
sent the molecular link between arterial calciﬁcation and bone
resorption. The purpose of this study was to determine whether
OPG and/or RANKL mediate the observed association between
coronary and bone calciﬁcation in postmenopausal women.
METHODS: Among the members of the Rancho Bernardo lon-
gitudinal study, 92 postmenopausal women (aged 58–81 years)
taking estrogen therapy (ET) who underwent assessment of bone
mineral density (BMD) and coronary artery calciﬁcation (CAC)
and had serum OPG and RANKL levels measured between
1998–2002 are the basis of this report. RESULTS: Neither OPG
nor RANKL levels varied among subjects with and without CAC
in multivariate analysis. Increase in BMD at the hip was associ-
ated with decrease in CAC (OR = 0.52; 95% CI: 0.29–0.93)
independent of age, fat-free mass, HDL cholesterol, current
smoking, and use of cholesterol-lowering medications. Other
skeletal sites demonstrated a similar pattern. Addition of
RANKL and/or OPG in the model had minimal effect on the
magnitude or statistical signiﬁcance of the BMD-CAC associa-
tion. Additionally, a test of interaction indicated that RANKL
and OPG are not signiﬁcant effect modiﬁers of the association.
CONCLUSION: Serum OPG and RANKL do not account for
the observed association between bone and coronary artery
calciﬁcation among postmenopausal women using ET.
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OBJECTIVE: Beta-blocker therapy, well established in the treat-
ment of CHF, is considered contraindicated in patients with
concomitant diabetes by many physicians due to concerns of
increased incidence of hypoglycemia, worsening dyslipidemia,
and decreased insulin sensitivity. Purpose of this study is to
determine the association between beta-blocker therapy and
hospitalization in patients with chronic heart failure (CHF) and
diabetes. METHODS: The study was a retrospective analysis
utilizing the pharmacy, inpatient and outpatient claims linked
with eligibility ﬁles for persons enrolled in the Georgia Medicaid
beneﬁts through the year 2001. Patients who received both diag-
nosis of chronic heart failure and diabetes were identiﬁed. The
study cohort was further categorized into treatment and com-
parison groups according to their exposure to Beta-blocker. A
stepwise logistic regression analysis was employed to assess the
association between taking beta-blocker and hospitalization
among CHF patients with diabetes. RESULTS: Three hundred
ninety patients with beta-blocker exposure and 642 not-exposed
patients were identiﬁed. Two hundred thirty eight patients were
hospitalized and 799 had no hospitalization. Majority of the
cohort was female 788 (76.36%), black 531 (51.45%) and in the
age group of 40–65 years 966 (93.60%). Metoprolol was the
most commonly used beta-blocker with 12,149 claims (51.83%)
followed by Carvedilol 6169 (26.32%). The most common
co-morbid conditions among patients were found to be Hyper-
tension, Ischemic Heart Disease and Chronic Obstructive Pulmo-
nary Disease. Diuretics, ACE inhibitors and Digoxin use were
found to be the common concurrent therapy taken by the
patients. After controlling for factors like age, race, gender,
common co-medications and co-morbid conditions, there was no
signiﬁcant association between hospitalization and beta-blockers
use in patients with Chronic Heart Failure and Diabetes.
CONCLUSION: Despite the potential contraindication, the
utilization of beta-blocker does not lead to a higher rate of
hospitalization among CHF patients with diabetes.
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OBJECTIVE: The Blood Pressure Success Zone (BPSZ) Program
is a nationwide initiative which provides blood pressure manage-
ment education to hypertensive patients and a complimentary
trial of antihypertensive medications. The BPSZ-BLISS (Longitu-
dinal Observational Study of Success) is an observational study
to evaluate BPSZ program effectiveness on blood pressure (BP)
control, compliance, persistence and treatment satisfaction.
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BPSZ-BLISS is naturalistic and designed to obtain outcomes
data with minimum impact on BPSZ and clinical processees.
METHODS: Data are entered, using an Interactive Voice
Response System (IVRS), by MDs at baseline and at usual care
visits up to 12 +/- 2 months; subjects report self-measured BPs,
persistence, compliance, and treatment satisfaction at 3, 6, and
12 months. Final cohort characteristics are reported. RESULTS:
After 18 months, 10,067 eligible US subjects have been enrolled
by 734 IRB approved MDs. Subjects are 48% male, mean aged
56 (SD = 13) years, and 27% newly diagnosed with hyperten-
sion. Most are Caucasian (70%), or African-American (22%);
only 5% are Hispanic, or other (3%) ethnicity. Median diastolic
and systolic BPs qualifying subjects (without diabetes or kidney
disease) for study enrollment were 98 mmHg and 154 mmHg
respectively. In chronic hypertensives, most common anti-
hypertension medications prior to baseline were angiotensin
receptor blockers (ARB) or ARB combination (38%), calcium
channel blockers (CCB) or CCB combination (32%), beta block-
ers (BB) or BB combination (27%), or angiotensin converting
enzyme inhibitors (ACE I) or ACE I combination (24%), and
diuretics (18%). Automated IVRS validations have maintained
data quality (5% error on key variables). Completion of
patient follow-up is scheduled for June 2008. CONCLUSION:
An innovative design and automated data management and
quality control methodologies have been shown to be feasible to
collect MD and patient data in a nationwide health education
program. Baseline study data are available for comparison with
other real-world datasets.
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OBJECTIVE: To describe the trends of intra-hospital mortality,
length of stay (LOS) and readmissions of patients with acute
stroke at the National Healthcare Group (NHG), Singapore,
2000–2006. METHODS: All patients aged 21+ years dis-
charged with a primary diagnosis of stroke (ICD9CM 430-435)
from the three public hospitals in NHG from January 2000 to
December 2006 were studied. Data extracted from computer-
ized datamart included demographic characteristics; co-morbid
conditions; and outcomes of interest; i.e. LOS, intra-hospital
mortality, and readmissions within one, three, and six months
of discharge. Patients were stratiﬁed into hemorrhagic stroke
(HS), ischemic stroke (IS) and transient ischaemic attack (TIA).
Data were analysed by one-way ANOVA, logistic regression
and chi-square test using SPSSv15. RESULTS: During the
period 2000–2006, there was a total of 22,428 deaths and dis-
charges of patients with acute stroke. Prevalence of hyperten-
sion was highest in HS (>60%), with the rate decreasing
signiﬁcantly from 2000–2006 (p = 0.001). However, the preva-
lence of dyslipidaemia was highest among in IS, with a signiﬁ-
cant increase in rate in all during the period in all types of
stroke (p < 0.001). Overall, HS was associated with highest
intra-hospital mortality rate (95%CI: 22.3%–24.3%) and
longest average LOS (95%CI: 17.1–18.7 days). A signiﬁcant
increasing trend in average LOS (p < 0.001) was noted in both
HS and IS. Readmissions within the 1-month, 3-month, and
6-month all decreased signiﬁcantly over the period (p < 0.001).
The readmission rates within 1-month for HS and IS were
higher than that of TIA, while there were no difference in read-
mission rates within three (5%) and six (6%) months for all
stroke types. CONCLUSION: More studies into the causes of
increased LOS should be carried out. Targeted primary inter-
ventions are needed to address the high rates of hypertension
among those with IS and the increasing trend in dyslipidaemia
among all types of stroke.
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OBJECTIVE: Many patients with dyslipidemia fail to reach
treatment goals on the lowest dose of a single drug. We assessed
the effects of intensiﬁed lipid-modifying therapies on the
expected rates of coronary events among a cohort of 10,000
people aged 50+ years with established CHD and high non-HDL-
cholesterol levels. METHODS: This model-based analysis used
data from the recent SEACOAST clinical trial and a published
equation for secondary prevention of CHD from the Framing-
ham Heart Study (FHS), based on the total-cholesterol/HDL-C
ratio, to calculate the expected number of CHD events over ﬁve
years. Findings from the SEACOAST trial showed that patients
treated with a ﬁxed-dose extended release niacin/simvastatin
(ERN/S) combination had signiﬁcant improvements in non-
HDL-C, HDL-C, and triglyceride levels when compared to
patients treated with simvastatin therapy alone. Age, sex, and
coronary risk-factor data for patients with CHD and non-
HDL-C cholesterol >130 mg/dL were obtained from 1999–2002
NHANES. The drugs of interest included simvastatin alone and
ERN/S. The scenarios of interest reﬂected increasing the dose of
simvastatin or adding ERN to simvastatin. RESULTS: We esti-
mated that 1741 CHD events would occur over ﬁve years among
10,000 patients treated with 20 mg of simvastatin. The number
of CHD events would decrease by 8.9% with 1000/20 mg of
ERN/S. Relative to a maximum dose of 80 mg of simvastatin,
intermediate (1000/40 mg) and maximum doses (2000/40 mg) of
ERN/S would reduce CHD events by 4.9 and 11.1 percentage
points, respectively. CONCLUSION: Based on this FHS risk
model for a secondary prevention population with elevated
non-HDL cholesterol, intensifying lipid-modifying therapy with
selected ﬁxed-dose ERN/S combinations may reduce the number
of CHD events relative to the use of simvastatin monotherapy.
Conﬁrmation of the predicted clinical events of the ﬁxed-dose
combination in a secondary prevention patient population would
be useful.
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OBJECTIVE: Statin therapy is fundamental in cardiovascular
disease prevention. Beneﬁt of statin therapy is proportional to
low-density lipoprotein cholesterol reduction and no threshold
has been identiﬁed as a limitation below which beneﬁt is
reduced. Serious side-effects are infrequent, but the adverse
experience with the agent Cerivastatin justiﬁes scrutiny of the
relationship between therapeutic effect and the risk of side-
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